Meeting
2021 ASCO Annual Meeting
A novel biosignature identifies DCIS patients with a poor biologic subtype with an unacceptably high rate of local recurrence after breast conserving surgery and radiotherapy.
Authors
Frank Vicini
NRG Oncology, and 21st Century Oncology, Pontiac, MI
Frank Vicini , Chirag Shah , Pat W. Whitworth , Steven C Shivers , Fredrik Warnberg , Bruce Mann , Troy Bremer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 513)
DOI
10.1200/JCO.2021.39.15_suppl.513
Abstract #
513
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A novel biosignature to assess residual risk in ductal carcinoma in situ (DCIS) patients after standard treatment.
First Author: Troy Bremer
Poster
2021 ASCO Annual Meeting
Role of 21- gene recurrence score in patients age ≥70 with T1N0 ER/PR+ HER2- breast cancer treated with breast-conserving surgery and endocrine therapy.
First Author: Neil Chandrabhan Chevli
Poster
2019 ASCO Annual Meeting
Risk stratification in earl- stage luminal breast cancer patients treated with and without RT.
First Author: Charlotta Wadsten
Poster
2013 Breast Cancer Symposium
Triple-negative breast cancer and likelihood of nodal metastates.
First Author: Alexandra Gangi